InnovAge (NASDAQ:INNV - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, Zacks reports. InnovAge had a negative return on equity of 9.45% and a negative net margin of 3.19%. InnovAge updated its FY 2025 guidance to EPS.
InnovAge Stock Up 2.2 %
Shares of NASDAQ:INNV traded up $0.07 during trading on Friday, hitting $3.29. The company's stock had a trading volume of 53,594 shares, compared to its average volume of 59,102. The company has a market capitalization of $444.94 million, a PE ratio of -17.32 and a beta of 0.37. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.21 and a current ratio of 1.16. InnovAge has a fifty-two week low of $3.12 and a fifty-two week high of $6.69. The business has a 50 day moving average price of $3.98 and a two-hundred day moving average price of $5.19.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on INNV. KeyCorp initiated coverage on shares of InnovAge in a research report on Friday, October 11th. They set a "sector weight" rating on the stock. JPMorgan Chase & Co. reissued an "underweight" rating and issued a $5.00 price target on shares of InnovAge in a research note on Tuesday, December 17th.
Get Our Latest Stock Report on INNV
About InnovAge
(
Get Free Report)
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.
Recommended Stories
Before you consider InnovAge, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InnovAge wasn't on the list.
While InnovAge currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
